Table 2 –
Biopsy characteristics at each sequential surveillance biopsy after diagnosis for 558 participants in the training set
| Parameter | Initial biopsy First | Subsequent surveillance biopsies | ||||||
|---|---|---|---|---|---|---|---|---|
| Second | Third | Fourth | Fifth | Sixth | Seventh | Eighth | ||
| Biopsies (n) | 319 | 246 | 108 | 34 | 20 | 10 | 3 | 1 |
| CR for previous biopsya | ||||||||
| Median (IQR) | 0.08 (0.08) | 0.07 (0.17) | 0.08 (0.17) | 0.06 (0.12) | 0.06 (0.12) | 0 (0.07) | 0.11 (0.06) | 0 (0) |
| Missing, n (%) | 0 | 5 (2) | 5 (5) | 0 | 0 | 0 | 0 | 0 |
| Median MCRb (IQR) | 0.08 (0.08) | 0.11 (0.08) | 0.13 (0.15) | 0.17 (0.13) | 0.10 (0.17) | 0.14 (0.15) | 0.17 (0.08) | 0.17 (0.00) |
| Negative biopsiesc, n (%) | ||||||||
| 0 | 319 (100) | 145 (59) | 44 (41) | 10 (29) | 4 (20) | 1 (10) | 1 (33) | 0 |
| 1 | 0 | 101 (41) | 38 (35) | 13 (38) | 6 (30) | 3 (30) | 2 (67) | 0 |
| 2 | 0 | 0 | 26 (24) | 6 (18) | 3 (15) | 1 (10) | 0 | 1 (100) |
| 3 | 0 | 0 | 0 | 5 (15) | 2 (10) | 3 (30) | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 | 5 (25) | 2 (20) | 0 | 0 |
| Median PV, cm3 (IQR) | 41.0 (26.5) | 38.0 (27.0) | 41.0 (27.0) | 48.5 (25.0) | 59.5 (36.5) | 43.5 (27.8) | 41.0 (19.5) | 97.0 (0.0) |
| Biopsy GS, n (%) | ||||||||
| Negative | 107 (34) | 95 (39) | 38 (35) | 11 (32) | 8 (40) | 6 (60) | 2 (67) | 0 |
| 6 | 152 (48) | 108 (44) | 48 (45) | 21 (62) | 10 (50) | 3 (30) | 1 (33) | 1 (100) |
| 7 | 58 (18) | 42 (17) | 21 (19) | 2 (6) | 2 (10) | 1 (10) | 0 | 0 |
| 8 | 1 (0) | 1 (0) | 1 (1) | 0 | 0 | 0 | 0 | 0 |
| 9 | 1 (0) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CR = core ratio; IQR = interquartile range; MCR = maximum CR; PV = prostate volume; GS = Gleason score.
a
CR is defined as the number of biopsy cores containing cancer divided by the total number of biopsy cores in the previous biopsy.
b
MCR among all previous biopsies.
c
Number of surveillance biopsies in which no cancer was found.